OVID: SEC Form 8-K filed by Ovid Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for OVID
Across the 4 sessions after earlier OVID headlines, the stock closed higher 1 times and lower 3 times, with a median move of 5.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OVID | SPY |
|---|---|---|---|
| Dec 18, 2025 | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) | -9.5% | +0.8% |
| Dec 11, 2025 | Roth Capital initiated coverage on Ovid Therapeutics with a new price target | +1.9% | +0.2% |
| Dec 2, 2025 | Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | -13.3% | +0.2% |
| Nov 17, 2025 | Leerink Partners initiated coverage on Ovid Therapeutics | -0.4% | -0.9% |
Quantisnow market dataNASDAQ
OVID
Ovid Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for OVID
Full OVID profile on Quantisnow Follow OVID and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time